In this study we analyzed whether the polymorphisms 676T>G in the tumor necrosis factor receptor (TNFR) II gene and -308G>A in the TNFα promoter gene may influence the response grading to anti-TNFα therapy in rheumatoid arthritis. We enrolled and genotyped 105 RA patients treated with etanercept (n=55), infliximab (n=40) and adalimumab (n=10) for one year. The clinical response was evaluated according to the ACR criteria every 3 months. Patients with TNFRII 676TG genotype was significantly associated with lower ACR response compared to 676TT genotype, at 3 (OR 3.78 95%CI 1.07-13.31) and 12 months (OR 4.30 95%CI 1.16-15.99) of treatment. No significant association between TNFα -308G>A polymorphism and the clinical response was found. TNFRII 676TG genotype is associated with a lower response to anti-TNFα therapy, independently from the specific agent used. This polymorphism could become a useful genetic marker for predicting the different response grading to anti-TNFα therapy.

Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFα therapy in rheumatoid arthritis?

ONGARO, Alessia
Primo
;
DE MATTEI, Monica
Secondo
;
PELLATI, Agnese;CARUSO, Angelo;FERRETTI, Stefano;MASIERI, Federica Francesca;FOTINIDI, Maria;FARINA, Ilaria;TROTTA, Francesco
Penultimo
;
PADOVAN, Melissa
Ultimo
2008

Abstract

In this study we analyzed whether the polymorphisms 676T>G in the tumor necrosis factor receptor (TNFR) II gene and -308G>A in the TNFα promoter gene may influence the response grading to anti-TNFα therapy in rheumatoid arthritis. We enrolled and genotyped 105 RA patients treated with etanercept (n=55), infliximab (n=40) and adalimumab (n=10) for one year. The clinical response was evaluated according to the ACR criteria every 3 months. Patients with TNFRII 676TG genotype was significantly associated with lower ACR response compared to 676TT genotype, at 3 (OR 3.78 95%CI 1.07-13.31) and 12 months (OR 4.30 95%CI 1.16-15.99) of treatment. No significant association between TNFα -308G>A polymorphism and the clinical response was found. TNFRII 676TG genotype is associated with a lower response to anti-TNFα therapy, independently from the specific agent used. This polymorphism could become a useful genetic marker for predicting the different response grading to anti-TNFα therapy.
Ongaro, Alessia; DE MATTEI, Monica; Pellati, Agnese; Caruso, Angelo; Ferretti, Stefano; Masieri, Federica Francesca; Fotinidi, Maria; Farina, Ilaria; Trotta, Francesco; Padovan, Melissa
File in questo prodotto:
File Dimensione Formato  
s00296-008-0552-5.pdf

solo gestori archivio

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 368.62 kB
Formato Adobe PDF
368.62 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/523381
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 29
social impact